Oscar Segurado, MD, PhD, is the Chief Medical Officer for ASC Therapeutics, responsible for translational science into clinical development and global regulatory filings.

ASC Therapeutics is a fast-growing biotechnology company focused on developing curative gene- and cell-based therapies for rare blood and metabolic disorders. As a leading biopharmaceutical services company with over 14 years of experience in gene editing and stem cell technologies, we have established global R&D, regulatory and manufacturing capabilities for 3 platforms: Gene replacement therapy, initially focusing on maple syrup urine disease gene mutations and a second-generation factor VIII replacement for hemophilia A; in-vivo CRISPR gene editing, initially focusing on hemophilia A; and off-the-shelf allogeneic cell therapy, initially focusing on decidua stromal cells for graft-versus-host disease.

Former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Executive veteran with extensive global leadership experience in translational science, clinical development and global regulatory and medical affairs.

Author and co-author of over 100 peer-reviewed publications, including Nature and Lancet, books and medical articles and member of several scientific and medical societies. Forbes Council Board Member. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.